Last reviewed · How we verify
Glargine and Lispro insulin
Glargine and Lispro insulin, marketed by Universidad de Guanajuato, is a combination insulin therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk lies in the potential for increased competition once the patent expires.
At a glance
| Generic name | Glargine and Lispro insulin |
|---|---|
| Also known as | Glargine and Lispro |
| Sponsor | Universidad de Guanajuato |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes (PHASE3)
- Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) (NA)
- A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glargine and Lispro insulin CI brief — competitive landscape report
- Glargine and Lispro insulin updates RSS · CI watch RSS
- Universidad de Guanajuato portfolio CI